<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Etravirine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Etravirine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Etravirine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8902" href="/d/html/8902.html" rel="external">see "Etravirine: Drug information"</a> and <a class="drug drug_patient" data-topicid="12022" href="/d/html/12022.html" rel="external">see "Etravirine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F5606106"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Intelence</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868933"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Intelence</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F7291409"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiretroviral Agent</span>;</li>
<li>
<span class="list-set-name">HIV Agents (Anti-HIV Agents)</span>;</li>
<li>
<span class="list-set-name">Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)</span></li></ul></div>
<div class="block dop drugH1Div" id="F14290658"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Gene mutation and ARV resistance patterns should be evaluated (refer to https://www.iasusa.org/ for more information) when necessary.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b> Use in combination with other antiretroviral agents.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥2 years weighing at least 10 kg and Adolescents, antiretroviral-experienced: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;20 kg: 100 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">20 kg to &lt;25 kg: 125 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">25 kg to &lt;30 kg: 150 mg twice daily</p>
<p style="text-indent:-2em;margin-left:6em;">≥30 kg: 200 mg twice daily</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109679"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥2 years and Adolescents: No dosage adjustments required. Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely.</p></div>
<div class="block dohp drugH1Div" id="F51109680"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥2 years weighing at least 10 kg and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No dosage adjustments required.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F5605725"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8902" href="/d/html/8902.html" rel="external">see "Etravirine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="54b359d7-24b9-4b96-9d31-710e220dc129">HIV-1 infection, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>HIV-1 infection, treatment:</b>
<b>Oral:</b> 200 mg twice daily in combination with other antiretrovirals.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990745"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to extensive protein binding, significant removal by hemodialysis or peritoneal dialysis is unlikely. </p></div>
<div class="block doha drugH1Div" id="F50988122"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F5605591"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported with background regimen in adults unless otherwise indicated. Reported incidences are for grades 2 to 4 unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (children and adolescents: 15%; adults: 10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercholesterolemia (grades 2 to 3: 8% to 20%), increased LDL cholesterol (grade 2: 13%), increased serum glucose (grades 2 to 3: 4% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (children and adolescents: all grades: ≥2%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction (&lt;2%), angina pectoris (&lt;2%), atrial fibrillation (&lt;2%), syncope (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis (&lt;2%), night sweats (&lt;2%), prurigo (&lt;2%), xeroderma (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Diabetes mellitus (&lt;2%), dyslipidemia (&lt;2%), gynecomastia (&lt;2%), increased serum triglycerides (4% to 9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (&lt;2%), anorexia (&lt;2%), constipation (&lt;2%), flatulence (&lt;2%), gastritis (&lt;2%), gastroesophageal reflux disease (&lt;2%), hematemesis (&lt;2%), increased serum amylase (grade 4: 2%), increased serum lipase (grade 4: 1%), pancreatitis (&lt;2%), retching (&lt;2%), stomatitis (&lt;2%), xerostomia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased white blood cell count (grade 4: 1%), hemolytic anemia (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure (&lt;2%), hepatitis (&lt;2%; including cytolytic hepatitis), hepatomegaly (&lt;2%), increased serum alanine aminotransferase (1% to 6%), increased serum aspartate aminotransferase (grade 3: 3%), liver steatosis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial swelling (&lt;2%), hypersensitivity reaction (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Immune reconstitution syndrome (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams (&lt;2%), amnesia (&lt;2%), anxiety (&lt;2%), confusion (&lt;2%), disorientation (&lt;2%), disturbance in attention (&lt;2%), drowsiness (&lt;2%), hypersomnia (&lt;2%), hypoesthesia (&lt;2%), lethargy (&lt;2%), nervousness (&lt;2%), nightmares (&lt;2%), paresthesia (&lt;2%), peripheral neuropathy (4%), seizure (&lt;2%), sleep disturbance (&lt;2%), tremor (&lt;2%), vertigo (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lipohypertrophy (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney failure (&lt;2%), increased serum creatinine (grades 2 to 3: 2% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (&lt;2%), dyspnea on exertion (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Intracranial hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Lipodystrophy</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any grade):</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myopathy (Tommasi 2010), rhabdomyolysis</p></div>
<div class="block coi drugH1Div" id="F5605587"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to etravirine or any component of the formulation; concomitant use with the hepatitis C combination regimen of ombitasvir, paritaprevir, ritonavir and with drugs containing dasabuvir.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F5605588"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).</p>
<p style="text-indent:-2em;margin-left:4em;">• Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome, resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves disease, polymyositis, Guillain-Barré syndrome, autoimmune hepatitis) later in therapy; further evaluation and treatment may be required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin reactions/hypersensitivity: Severe and possibly life-threatening skin reactions (including Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme) and hypersensitivity reactions ranging from rash (including grades 3/4 rash and drug rash with eosinophilia and systemic symptoms) and/or constitutional symptoms to occasional organ dysfunction (including hepatic failure) have been reported. Rash occurs most commonly in the first 6 weeks of therapy and is more frequent in females. Discontinue immediately with signs or symptoms of severe skin reaction or hypersensitivity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not for use in treatment-naive patients, or experienced patients without evidence of viral mutations conferring resistance to nonnucleoside reverse transcriptase inhibitors and protease inhibitors.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878719"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Rash is more common and severe in pediatric patients (2 years to &lt;18 years) than in adults, particularly those &lt;6 years of age and females; usually described as mild to moderate, pruritic, maculopapular skin eruptions (incidence: Children 2 to &lt;6 years: 50%; pediatric patients ≥6 years: 15%, adults: 10%). In pediatric patients, rash usually appeared in the second week of therapy and generally resolved within a week. Discontinue etravirine if severe rash (involving blistering, desquamation, mucosal involvement, ulceration, or fever) occurs.</p></div>
<div class="block foc drugH1Div" id="F5605757"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intelence: 25 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intelence: 100 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F5605504"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F6133123"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Etravirine Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $12.87 - $13.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $25.75 - $26.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Intelence Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $3.67</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $14.69</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $29.37</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868934"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Intelence: 25 mg [DSC], 100 mg, 200 mg</p></div>
<div class="block admp drugH1Div" id="F52614263"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer after meals. Swallow tablet whole with water; do not chew. If unable to swallow tablets, may disperse tablets in 5 mL water (enough to cover tablets), stir well (until milky appearance), add additional water (or may add milk or orange juice), and drink immediately. Rinse glass several times (with water, milk, or orange juice) and swallow entire contents to ensure administration of full dose. Do not use carbonated beverages or warm (&gt;40°C) drinks (including warm water).</p></div>
<div class="block adm drugH1Div" id="F5605728"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer after meals. Tablets should be swallowed whole. If unable to swallow whole tablets, may disperse tablets in water (5 mL [at least enough to cover tablets]); stir well (until water looks milky), then add ~15 mL of water, milk, or orange juice, and drink immediately. Tablets should not be placed in orange juice or milk without first adding water. Rinse glass several times (with water, milk, or orange juice) and swallow entire contents with each rinse to ensure administration of dose. Do not use carbonated beverages or warm (&gt;40°C) water.</p></div>
<div class="block sts drugH1Div" id="F5605671"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at USP controlled room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from moisture.</p></div>
<div class="block usep drugH1Div" id="F53570241"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of HIV-1 infection in combination with other antiretroviral agents (FDA approved in ages ≥2 years weighing at least 10 kg and adults); <b>Note:</b> HIV regimens consisting of <b>three</b> antiretroviral agents from at least <b>two</b> classes are strongly recommended.</p></div>
<div class="block mst drugH1Div" id="F13811173"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Etravirine [US and multiple international markets] may be confused with ethaverine [multiple international markets]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F5605666"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C19 (major), CYP2C9 (major), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak); <b>Induces</b> CYP3A4 (moderate)</p></div>
<div class="block dri drugH1Div" id="F5605665"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abemaciclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Abiraterone Acetate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Acalabrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALfentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALfentanil.  Management: If concomitant use of alfentanil and moderate CYP3A4 inducers is necessary, consider dosage increase of alfentanil until stable drug effects are achieved. Monitor patients for signs of opioid withdrawal.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ALPRAZolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ALPRAZolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">AmLODIPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of AmLODIPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apremilast: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Apremilast. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Artemether and Lumefantrine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Artemether and Lumefantrine. Specifically, concentrations of dihydroartemisinin (DHA), the active metabolite of artemether may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Artemether and Lumefantrine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Asunaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Atazanavir. Management: The combination of etravirine and atazanavir should be avoided unless atazanavir is boosted with ritonavir. The use of cobicistat instead of ritonavir has not been evaluated and is not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atogepant.  Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Atorvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avacopan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avacopan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avanafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avanafil. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Avapritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Avapritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Axitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bedaquiline: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Bedaquiline. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Belumosudil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benzhydrocodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Betibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Betibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bortezomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Bosutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brexpiprazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Brigatinib.  Management: Avoid concurrent use of brigatinib with moderate CYP3A4 inducers when possible. If combined, increase the daily dose of brigatinib in 30 mg increments after 7 days of treatment with the current brigatinib dose, up to maximum of twice the dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Buprenorphine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of BusPIRone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cabozantinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cabozantinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabis: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capivasertib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capivasertib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capmatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Capmatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cariprazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ceritinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Clarithromycin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A4 inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and impair its efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Clindamycin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Etravirine may decrease serum concentrations of the active metabolite(s) of Clopidogrel.  Management: Consider alternatives to clopidogrel in patients treated with etravirine. If combined, monitor for reduced clopidogrel effectiveness.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobicistat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobimetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Codeine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Copanlisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Copanlisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Crizotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Crizotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Etravirine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daclatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daclatasvir.  Management: Increase the daclatasvir dose to 90 mg once daily if used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapsone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dapsone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Daridorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Daridorexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Etravirine. Management: Avoid coadministration of etravirine and darunavir/cobicistat. No action is required if etravirine is combined with darunavir/ritonavir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasabuvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: CYP3A4 Inducers (Moderate) may increase the serum concentration of Dasatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deflazacort: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DexAMETHasone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DexAMETHasone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DiazePAM: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DiazePAM. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dienogest: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dienogest. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Etravirine may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DilTIAZem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DilTIAZem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disopyramide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dolutegravir: Etravirine may decrease the serum concentration of Dolutegravir.  Management: Avoid etravirine with dolutegravir unless with atazanavir/ritonavir, darunavir/ritonavir or lopinavir/ritonavir; avoid use with Dovato brand combination. Canada recommends using dolutegravir 50 mg twice daily when with etravirine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DroNABinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of DroNABinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dronedarone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Duvelisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Duvelisib.  Management: Avoid if possible. If used, on day 12 of combination increase duvelisib from 25 mg twice daily to 40 mg twice daily or from 15 mg twice daily to 25 mg twice daily. Resume prior duvelisib dose 14 days after stopping moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dydrogesterone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Dydrogesterone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elacestrant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elbasvir and Grazoprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elbasvir and Grazoprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elexacaftor, Tezacaftor, and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Eliglustat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Elivaldogene Autotemcel.  Management: Avoid use of antiretroviral medications for at least one month, or for the amount of time required for elimination of the retroviral medication, prior to stem cell mobilization and until the all apheresis cycles are finished<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elvitegravir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Elvitegravir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Entrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Entrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erdafitinib.  Management: Dose modifications of erdafitinib may be required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergonovine: Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of Ergonovine. Specifically, this would be most likely with delavrdine, while other Non-Nucleoside Reverse Transcriptase Inhibitors may be more likely to decrease the concentration of Ergonovine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Erlotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Estrogen Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etoposide Phosphate: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Etoposide Phosphate. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exemestane: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Exemestane. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fedratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fedratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Felodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">FentaNYL: CYP3A4 Inducers (Moderate) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Finerenone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: Etravirine may decrease the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fluvastatin: Etravirine may increase the serum concentration of Fluvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosamprenavir: Etravirine may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may increase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fosaprepitant. Specifically, CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosnetupitant: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fosnetupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fostamatinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Fostamatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fruquintinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Fruquintinib.  Management: Avoid this combination when possible. If combined, continue the same fruquintinib dose, but monitor for reduced fruquintinib efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganaxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ganaxolone.  Management: Avoid concomitant use of ganaxolone and moderate CYP3A4 inducers whenever possible. If combined, consider increasing the dose of ganaxolone, but do not exceed the maximum recommended daily dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gefitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemigliptin: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gemigliptin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Gepirone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glasdegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glasdegib.  Management: Avoid use of glasdegib and moderate CYP3A4 inducers whenever possible. If combined, increase glasdegib dose from 100 mg daily to 200 mg daily or from 50 mg daily to 100 mg daily. Resume previous glasdegib dose 7 days after discontinuation of the inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glecaprevir and Pibrentasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Glecaprevir and Pibrentasvir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">GuanFACINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of GuanFACINE.  Management: Increase extended-release guanfacine dose by up to double when initiating guanfacine in patients taking CYP3A4 inducers or if initiating a CYP3A4 inducer in a patient already taking extended-release guanfacine. Monitor for reduced guanfacine efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Etravirine may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins). This applies to atorvastatin, lovastatin and simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hormonal Contraceptives: Etravirine may decrease the serum concentration of Hormonal Contraceptives. Specifically, progestin concentrations may decrease. Etravirine may increase the serum concentration of Hormonal Contraceptives. Specifically, estrogen concentrations may increase. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">HYDROcodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydrocortisone (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrexafungerp: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrexafungerp. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ibrutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Idelalisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Idelalisib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ifosfamide: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Imatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Indinavir.  Management: Consider avoiding the combination of indinavir and moderate CYP3A4 inducers whenever possible due to the risk for decreased indinavir concentrations, reduced efficacy, and development of resistance. If combined, monitor for indinavir treatment failure.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Infigratinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Irinotecan Products: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, concentrations of SN-38 may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isavuconazonium Sulfate: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Moderate) may decrease isavuconazole serum concentrations. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isradipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Isradipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Istradefylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Itraconazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixabepilone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixabepilone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ixazomib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketamine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ketamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): May increase the serum concentration of Etravirine. Etravirine may decrease the serum concentration of Ketoconazole (Systemic).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lapatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Larotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Larotrectinib.  Management: Double the larotrectinib dose if used together with a moderate CYP3A4 inducer. Following discontinuation of the moderate CYP3A4 inducer, resume the previous dose of larotrectinib after a period of 3 to 5 times the inducer's half-life.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin.  Management: Avoid concomitant use of lefamulin with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lefamulin (Intravenous): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lefamulin (Intravenous).  Management: Avoid concomitant use of lefamulin (intravenous) with moderate CYP3A4 inducers unless the benefits outweigh the risks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lemborexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lemborexant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lenacapavir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Leniolisib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lercanidipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lercanidipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Letermovir: Etravirine may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levamlodipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levamlodipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levoketoconazole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Levomethadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lidocaine (Systemic): Etravirine may decrease the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">LinaGLIPtin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of LinaGLIPtin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lonafarnib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lopinavir: Etravirine may decrease the serum concentration of Lopinavir. Lopinavir may decrease the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorlatinib: CYP3A4 Inducers (Moderate) may enhance the hepatotoxic effect of Lorlatinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lorlatinib.  Management: Avoid use of lorlatinib with moderate CYP3A4 inducers. If such a combination must be used, increase lorlatinib to 125 mg daily. Monitor for reduced lorlatinib efficacy and consider closer monitoring of AST, ALT, and bilirubin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lovastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lovotibeglogene Autotemcel: Antiretroviral Agents may diminish the therapeutic effect of Lovotibeglogene Autotemcel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumateperone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lumateperone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lurasidone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Lurasidone.  Management: Monitor for decreased lurasidone effects if combined with moderate CYP3A4 inducers and consider increasing the lurasidone dose if coadministered with a moderate CYP3A4 inducer for 7 or more days.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macimorelin: Etravirine may diminish the diagnostic effect of Macimorelin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macitentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Macitentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maraviroc: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice/day, but only if not receiving a strong CYP3A4 inhibitor. Not recommended for pediatric patients not also receiving a strong CYP3A4 inhibitor. Contraindicated in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Maribavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mavacamten. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mefloquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mefloquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Meperidine: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Meperidine. Specifically, concentrations of normeperidine, the CNS stimulating metabolite, may be increased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Meperidine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MethylPREDNISolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MethylPREDNISolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mexiletine: Etravirine may decrease the serum concentration of Mexiletine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mianserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mianserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midostaurin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Midostaurin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of MiFEPRIStone.  Management: Avoid combined use in patients treated for Cushing's disease. When used for pregnancy termination, mifepristone efficacy may be reduced and an alternative pregnancy termination procedure may be warranted. Ensure a follow-up assessment after combined use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirodenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mirodenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mitapivat.  Management: Consider alternatives to this combination when possible. If combined, monitor hemoglobin and titrate mitapivat beyond 50 mg twice daily, if needed, but do not exceed doses of 100 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Mobocertinib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Mobocertinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naldemedine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naloxegol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nelfinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Netupitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Netupitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NIFEdipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilotinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilvadipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nilvadipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NiMODipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of NiMODipine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Etravirine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nisoldipine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olaparib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Olutasidenib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Omaveloxolone. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orelabrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Orelabrutinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Orlistat: May decrease the serum concentration of Antiretroviral Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Osimertinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Osimertinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">OxyCODONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PACLitaxel (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PACLitaxel (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pacritinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palbociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palovarotene: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Palovarotene. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PAZOPanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pemigatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pemigatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Perampanel.  Management: Increase perampanel starting dose to 4 mg/day if used with moderate CYP3A4 inducers. Increase perampanel dose by 2 mg/day no more than once weekly based on response and tolerability. Dose adjustments may be needed if the inducer is discontinued.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: Etravirine may decrease the serum concentration of Phosphodiesterase 5 Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimavanserin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pimavanserin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Piperaquine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Piperaquine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pirtobrutinib.  Management: Avoid concomitant use if possible. If combined, if the current pirtobrutinib dose is 200 mg once daily, increase to 300 mg once daily. If current pirtobrutinib dose is 50 mg or 100 mg once daily, increase the dose by 50 mg.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitavastatin: Etravirine may increase the serum concentration of Pitavastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PONATinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PONATinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pralsetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pralsetinib.  Management: If this combo cannot be avoided, increase pralsetinib dose from 400 mg daily to 600 mg daily; from 300 mg daily to 500 mg daily; and from 200 mg daily to 300 mg daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Praziquantel: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Praziquantel.  Management: Consider alternatives to this combination whenever possible. If combined, monitor closely for reduced praziquantel efficacy. If possible, stop the moderate CYP3A4 inducer 2 to 4 weeks before praziquantel initiation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PrednisoLONE (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PredniSONE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Pretomanid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">QUEtiapine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QUEtiapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNIDine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: CYP3A4 Inducers (Moderate) may decrease the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quizartinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Quizartinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: Etravirine may decrease the serum concentration of Raltegravir.  Management: Concurrent use of etravirine with once-daily raltegravir (Isentress HD) is not recommended. Concurrent use of other raltegravir products with etravirine does not require any dose change.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Regorafenib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Regorafenib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Regorafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repaglinide: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repaglinide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Repotrectinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reverse Transcriptase Inhibitors (Non-Nucleoside): May enhance the adverse/toxic effect of other Reverse Transcriptase Inhibitors (Non-Nucleoside). Reverse Transcriptase Inhibitors (Non-Nucleoside) may decrease the serum concentration of other Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, efavirenz and nevirapine may decrease the serum concentrations of other non-nucleoside reverse transcriptase inhibitors. Reverse Transcriptase Inhibitors (Non-Nucleoside) may increase the serum concentration of other Reverse Transcriptase Inhibitors (Non-Nucleoside). Specifically, delavirdine may increase the serum concentration of etravirine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ribociclib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ribociclib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Etravirine. Management: Avoid use of rifabutin with etravirine in patients also taking a protease inhibitor/ritonavir. Rifabutin (300 mg daily) may be used with etravirine if etravirine is administered without a protease inhibitor/ritonavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of Etravirine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rimegepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rimegepant. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ripretinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ripretinib.  Management: Avoid this combination if possible. If concomitant use is required, increase ripretinib to 150 mg twice daily. Decrease ripretinib to 150 mg once daily 14 days after stopping a moderate CYP3A4 inducer. Monitor patients for ripretinib response and toxicity<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of RisperiDONE. CYP3A4 Inducers (Moderate) may decrease the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritlecitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ritlecitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May decrease the serum concentration of Etravirine. Management: Avoid concomitant use of etravirine with antiviral doses of ritonavir; use with ritonavir-boosted fosamprenavir or with ritonavir-boosted tipranavir is also not recommended.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roflumilast (Systemic): CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Roflumilast (Systemic). CYP3A4 Inducers (Moderate) may decrease the serum concentration of Roflumilast (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rolapitant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Rolapitant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Samidorphan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Samidorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selpercatinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Selumetinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sildenafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sildenafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simeprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Simvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Conventional): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Conventional). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus (Protein Bound): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sirolimus (Protein Bound). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sonidegib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sotorasib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Sparsentan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Etravirine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUFentanil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Suvorexant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Suvorexant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tadalafil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tadalafil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tamoxifen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tasimelteon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tasimelteon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tazemetostat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Temsirolimus: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Temsirolimus. Specifically, sirolimus concentrations may be decreased. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Temsirolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tetrahydrocannabinol and Cannabidiol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tezacaftor and Ivacaftor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiotepa: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Thiotepa. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Thiotepa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ticagrelor. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Etravirine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tivozanib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tivozanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tofacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tolvaptan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Toremifene: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Toremifene. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Toremifene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trabectedin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Trabectedin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraZODone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of TraZODone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Triazolam: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Triazolam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tucatinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Tucatinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ubrogepant: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ubrogepant.  Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a moderate CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Upadacitinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Upadacitinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP3A4 Inducers (Moderate) may decrease serum concentrations of the active metabolite(s) of Valbenazine. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: CYP3A4 Inducers (Moderate) may increase serum concentrations of the active metabolite(s) of Vandetanib. CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vandetanib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vemurafenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verapamil: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Verapamil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vilazodone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voclosporin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vonoprazan: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vonoprazan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vorapaxar: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Etravirine may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Etravirine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxelotor: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxelotor.  Management: Avoid concomitant use of voxelotor and moderate CYP3A4 inducers. If unavoidable, increase the voxelotor dose to 2,000 mg once daily. For children ages 4 to less than 12 years, weight-based dose adjustments are required. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voxilaprevir: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zaleplon: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zaleplon. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zanubrutinib.  Management: Avoid this combination if possible. If coadministration of zanubrutinib and a moderate CYP3A4 inducer is required, increase the zanubrutinib dose to 320 mg twice daily.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zopiclone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zopiclone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuranolone: CYP3A4 Inducers (Moderate) may decrease the serum concentration of Zuranolone. <i> Risk X: Avoid combination</i></p></div>
<div class="block foi drugH1Div" id="F5605669"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food increases absorption of etravirine by ~50%. Management: Take after meals and maintain adequate hydration, unless instructed to restrict fluid intake.</p></div>
<div class="block dic drugH1Div" id="F5605672"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take after meals.</p></div>
<div class="block rep_considerations drugH1Div" id="F49661579"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Contraception is not required to initiate or continue antiretroviral therapy.</p>
<p style="text-indent:0em;margin-top:2em;">The Health and Human Services (HHS) perinatal HIV guidelines do not recommend use of etravirine (except in special circumstances) for patients with HIV infection who are not yet pregnant but are trying to conceive.</p>
<p style="text-indent:0em;margin-top:2em;">Maximum viral suppression sustained below the limits of detection prior to conception is recommended for all persons with HIV who are planning a pregnancy. Optimization of the health of the person who will become pregnant is recommended. Selection of or changes to a specific antiretroviral regimen prior to pregnancy should be done as part of a shared decision-making process. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for couples planning a pregnancy when one or both partners are diagnosed with HIV may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block pri drugH1Div" id="F5605509"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Etravirine has a variable (moderate to high) level of transfer across the human placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Only limited data have been reported to the antiretroviral pregnancy registry and information is insufficient to evaluate teratogenic effects in humans. Maternal antiretroviral therapy (ART) may be associated with adverse pregnancy outcomes, including preterm birth, low birth weight, and small for gestational age infants. Actual risks may be influenced by maternal factors, such as disease severity, gestational age at initiation of therapy, and specific ART regimen; therefore, close fetal monitoring is recommended. Because there is clear benefit to appropriate treatment, maternal ART should not be withheld due to concerns for adverse neonatal outcomes. Long-term follow-up is recommended for all infants exposed to antiretroviral medications; children not diagnosed with HIV but who were exposed to ART in utero or as a neonate and develop significant organ system abnormalities of unknown etiology (particularly of the CNS or heart) should be evaluated for potential metabolic dysfunction.</p>
<p style="text-indent:0em;margin-top:2em;">The Health and Human Services (HHS) perinatal HIV guidelines do not recommend use in antiretroviral-naive pregnant patients; use is not recommended (except in special circumstances) in pregnant patients who have had ART therapy in the past but are restarting, or who require a new ART regimen (due to poor tolerance or poor virologic response of current regimen). In addition, patients who become pregnant while taking etravirine may continue if viral suppression is effective and the regimen is well tolerated.</p>
<p style="text-indent:0em;margin-top:2em;">The pharmacokinetics of etravirine are not significantly altered in pregnancy and dose adjustment is not needed (limited data).</p>
<p style="text-indent:0em;margin-top:2em;">ART is recommended for all pregnant people with HIV to maximize their health, maintain the viral load below the limit of detection and reduce the risk of perinatal transmission. Selection of or changes to a specific antiretroviral regimen during pregnancy should be done as part of a shared decision-making process. Patients on fully suppressive regimens prior to pregnancy generally may continue the same regimen considering known pregnancy outcomes and pharmacokinetic data. Monitoring of patients who are pregnant is more frequent than in patients who are not pregnant. ART initiated during pregnancy can be modified after delivery. In most cases, recommendations from the HHS perinatal HIV guidelines (based on data obtained from cisgender women) can be applied to transgender and gender diverse people assigned female sex at birth.</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to ART is ongoing. Health care providers should enroll all patients exposed to antiretroviral medications during pregnancy in the Antiretroviral Pregnancy Registry (1-800-258-4263). Enrollment should be done as early in pregnancy as possible.</p>
<p style="text-indent:0em;margin-top:2em;">Health care providers caring for pregnant patients with HIV and their infants may contact the National Perinatal HIV Hotline (1-888-448-8765) for clinical consultation (HHS [perinatal] 2023).</p></div>
<div class="block mopp drugH1Div" id="F53570239"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">HIV: General recommendations: Management of HIV infection requires extensive monitoring; refer to current guidelines (<a href="/external-redirect?target_url=https%3A%2F%2Fclinicalinfo.hiv.gov%2Fen%2Fguidelines&amp;token=nbsXe3i4qfUea5RCPRHtOXmm4jIHQPk10%2Bpt6G4BSzQwKJFM0Nvf8hDv6AkFR6Vg&amp;TOPIC_ID=87706" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines</a>) for additional guidance. Antiretroviral drug-resistance testing is recommended before initiation of therapy in treatment-naive patients. After initiation of or change in antiretroviral therapy regimen, pediatric patients should be evaluated for clinical adverse effects and treatment adherence at 1 to 2 weeks, and laboratory testing for drug toxicity should occur at 2 to 4 weeks; monitor for therapy adherence, effectiveness, and toxicities every 3 to 4 months.</p>
<p style="text-indent:-2em;margin-left:2em;">Drug-specific monitoring: Frequency may vary based on several factors including age, concomitant therapy, and clinical response; refer to current guidelines for additional information.</p>
<p style="text-indent:-2em;margin-left:2em;">Lipid profiles (triglycerides), hepatic function tests (bilirubin, LFTs): Baseline and periodically with therapy; skin rash or hypersensitivity.</p></div>
<div class="block rerp drugH1Div" id="F53569622"><span class="drugH1">Reference Range</span>
<p style="text-indent:0em;display:inline">Pediatric therapeutic reference range not established; in adults (n=59), a trough concentration &gt;300 ng/mL was associated with virologic success in a single study (Calcagno 2014)</p></div>
<div class="block pha drugH1Div" id="F5605755"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a non-nucleoside reverse transcriptase inhibitor, etravirine has activity against HIV-1 by binding to reverse transcriptase. It consequently blocks the RNA-dependent and DNA-dependent DNA polymerase activities, including HIV-1 replication. It does not require intracellular phosphorylation for antiviral activity. </p></div>
<div class="block phk drugH1Div" id="F5605679"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Pharmacokinetic data suggests that with comparable dosing, exposure in pediatric patients ≥2 years of age is similar to adult patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Increased 50% with food</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 99.9%; primarily to albumin and alpha<sub>1</sub>-acid glycoprotein</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic, primarily by CYP3A4, 2C9, and 2C19; major metabolites exhibit ~10% of parent drug activity against wild-type HIV</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 41 hours (± 20 hours)</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 2.5 to 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (94%, up to 86% as unchanged drug); urine (1%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F10961935"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Intellence</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Intelence</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-24861522">
<a name="24861522"></a>Calcagno A, Marinaro L, Nozza S, et al. Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Res</i>. 2014;108:44-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etravirine-pediatric-drug-information/abstract-text/24861522/pubmed" id="24861522" target="_blank">24861522</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf" target="_blank">http://aidsinfo.nih.gov/contentfiles/lvguidelines/pediatricguidelines.pdf</a>. Updated March 1, 2016. Accessed July 11, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intelence.1">
<a name="Intelence.1"></a>Intelence (etravirine) [prescribing information]. Horsham, PA: Janssen Products LP; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Intelence.2">
<a name="Intelence.2"></a>Intelence (etravirine) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19710593">
<a name="19710593"></a>Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. <i>AIDS.</i> 2009;23(17):2289-2300.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etravirine-pediatric-drug-information/abstract-text/19710593/pubmed" id="19710593" target="_blank">19710593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17617271">
<a name="17617271"></a>Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (Etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. <i>Lancet.</i> 2007;370(9581):39-48.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etravirine-pediatric-drug-information/abstract-text/17617271/pubmed" id="17617271" target="_blank">17617271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17617270">
<a name="17617270"></a>Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. <i>Lancet. </i>2007;370(9581):29-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etravirine-pediatric-drug-information/abstract-text/17617270/pubmed" id="17617270" target="_blank">17617270</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Public Health Agency of Canada (PHAC). Canadian Guidelines on Sexually Transmitted Infection. Last modified December 2013. <a href="http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php" target="_blank">http://www.phac-aspc.gc.ca/std-mts/sti-its/index-eng.php</a>. Accessed December 30, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20386384">
<a name="20386384"></a>Tommasi C, Tempestilli M, Fezza R, et al. A rare case of severe myopathy associated with etravirine use. <i>AIDS</i>. 2010;24(7):1088-1090. doi:10.1097/QAD.0b013e3283382f65<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/etravirine-pediatric-drug-information/abstract-text/20386384/pubmed" id="20386384" target="_blank">20386384</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  US Department of Health and Human Services (HHS) Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. <a href="https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new</a>. Updated January 31, 2023. Accessed February 23, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 87706 Version 323.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
